Skor CHADS-P2A2RC sebagai Prediktor KKVM Selama 30 Hari pada Pasien Imaest yang Menjalani Terapi Intervensi Koroner Perkutan di RSUP H. Adam Malik Medan

Abstract

Background. In most developed countries, coronary heart disease is one of the main causes of death. In patients with acute myocardial infarction, the prediction of major adverse cardiovascular events (MACE) is an important tool that has been widely adopted in prevention and early intervention. The CHADS-P2A2RC score can be used to predict risk and can be used to identify patients at high risk of thromboembolism, ischemic stroke, CVC and all cause death among coronary angiography patients without atrial fibrillation. Methode. This study is an observational analytic study conducted in a prospective cohort to assess the CHADS-P2A2RC score as a predictor of major cardiovascular events for 30 days in STEMI patients undergoing percutaneous intervention therapy at Haji Adam Malik Medan General Hospital rom May 2022- February 2023. The sample from this study were IMAEST patients undergoing percutaneous intervention therapy, according to the inclusion and exclusion criteria. Data is then collected and analyzed. Results. In this study, a total of 68 samples were obtained with 57 male samples (83.8%) and 11 (16.2%) female patients. The discriminated value of the CHADSP2A2RC score was assessed using the Receiver Operating Characteristic (ROC) method, with an AUC value of 0.756 with confidence intervals of 0.639 and 0.860 and a significance p = <0.001. So from the results of the analysis it was found that the CHADS-P2A2RC score had good predictive ability in predicting MACE events. The discrimination value of the CHA2DS2-VASc score assessed by AUC was 0.703 with a confidence interval of 0.571 – 0.836 and a significance of p = 0.005. The discriminatory value of the GRACE score assessed by AUC was 0.655 with a confidence interval of 0.519 – 0.790 and a significance p = 0.033. So it can be concluded that the CHADS-P2A2RC score has better diagnostic ability than the CHA2DS2-VASc and GRACE scores. Conclusion. The CHADS-P2A2RC score can be used to predict the incidence of MACE for 30 days in patients with STEMI undergoing percutaneous coronary intervention